BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 30497316)

  • 1. Clinical value of the quantitation of average daily platelet increase during the recovery period in childhood acute lymphoblastic leukaemia.
    Wang Y; Zhang G; Ye L; Dai Q; Peng L; Chen L; Chen Q; Jiang Y; Gao J
    Platelets; 2019; 30(7):923-926. PubMed ID: 30497316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prognostic Value of Average Daily Platelet Increase in Childhood B-cell Acute Lymphoblastic Leukemia Patients].
    Chen L; Chen Q; Wang YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Apr; 30(2):413-417. PubMed ID: 35395972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined use of peripheral blood blast count and platelet count during and after induction therapy to predict prognosis in children with acute lymphoblastic leukemia.
    Dai Q; Shi R; Zhang G; Yang H; Wang Y; Ye L; Peng L; Guo S; He J; Jiang Y
    Medicine (Baltimore); 2021 Apr; 100(15):e25548. PubMed ID: 33847682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remission.
    Faderl S; Thall PF; Kantarjian HM; Estrov Z
    Br J Haematol; 2002 Jun; 117(4):869-74. PubMed ID: 12060122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].
    Xu XJ; Tang YM; Song H; Shi SW; Yang SL; Shen HQ; Wei J; Xu WQ; Pan BH; Zhao FY
    Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):180-4. PubMed ID: 20426951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic study of continuous variables (white blood cell count, peripheral blast cell count, haemoglobin level, platelet count and age) in childhood acute lymphoblastic leukaemia. Analysis Of a population of 1545 children treated by the French Acute Lymphoblastic Leukaemia Group (FRALLE).
    Donadieu J; Auclerc MF; Baruchel A; Perel Y; Bordigoni P; Landman-Parker J; Leblanc T; Cornu G; Sommelet D; Leverger G; Schaison G; Hill C;
    Br J Cancer; 2000 Dec; 83(12):1617-22. PubMed ID: 11104555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?
    Balduzzi A; Di Maio L; Silvestri D; Songia S; Bonanomi S; Rovelli A; Conter V; Biondi A; Cazzaniga G; Valsecchi MG
    Br J Haematol; 2014 Feb; 164(3):396-408. PubMed ID: 24422724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical significance of dynamic monitoring the minimal residual disease in childhood B-lineage acute lymphoblastic leukemia by multiparameter flow cytometry].
    Guo DD; Zhao WL; Zhang YL; Pang L; Che L; He HL; Chai YH; Ji ZH; Ji XQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1346-51. PubMed ID: 23257430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience.
    Hassan HT; Krog C; Stockschläder M; Schleimer B; Zeller W; Krüger W; Erttmann R; Zander AR
    Anticancer Res; 1997; 17(1B):589-99. PubMed ID: 9066585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.
    Thörn I; Forestier E; Botling J; Thuresson B; Wasslavik C; Björklund E; Li A; Lindström-Eriksson E; Malec M; Grönlund E; Torikka K; Heldrup J; Abrahamsson J; Behrendtz M; Söderhäll S; Jacobsson S; Olofsson T; Porwit A; Lönnerholm G; Rosenquist R; Sundström C
    Br J Haematol; 2011 Mar; 152(6):743-53. PubMed ID: 21250970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rates and trends of childhood acute lymphoblastic leukaemia: an epidemiology study.
    Kakaje A; Alhalabi MM; Ghareeb A; Karam B; Mansour B; Zahra B; Hamdan O
    Sci Rep; 2020 Apr; 10(1):6756. PubMed ID: 32317670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic factors for childhood acute non-mature B-lymphoblastic leukemia].
    Jiang H; Gu LJ; Xue HL; Tang JY; Chen J; Pan C; Chen J; Xu C; Dong L; Zhou M
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):290-4. PubMed ID: 18554450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study of procoagulant platelet extracellular vesicles and P-selectin increase during induction treatment in acute lymphoblastic leukaemia paediatric patients: two new biomarkers of thrombogenic risk?
    Pluchart C; Barbe C; Poitevin G; Audonnet S; Nguyen P
    J Thromb Thrombolysis; 2021 Apr; 51(3):711-719. PubMed ID: 33247807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
    Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M; Jiang LM
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):333-6. PubMed ID: 18554462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction.
    Brisco MJ; Condon J; Hughes E; Neoh SH; Sykes PJ; Seshadri R; Toogood I; Waters K; Tauro G; Ekert H
    Lancet; 1994 Jan; 343(8891):196-200. PubMed ID: 7904666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia.
    Lovisa F; Zecca M; Rossi B; Campeggio M; Magrin E; Giarin E; Buldini B; Songia S; Cazzaniga G; Mina T; Acquafredda G; Quarello P; Locatelli F; Fagioli F; Basso G
    Br J Haematol; 2018 Mar; 180(5):680-693. PubMed ID: 29359790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.
    Boublikova L; Kalinova M; Ryan J; Quinn F; O'Marcaigh A; Smith O; Browne P; Stary J; McCann SR; Trka J; Lawler M
    Leukemia; 2006 Feb; 20(2):254-63. PubMed ID: 16341043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical Significance of Minimal Residual Disease in Risk Stratification and Prognosis of Childhood B-lineage Acute Lymphoblastic Leukemia].
    An FY; Zhang SH; Kong LJ; Liang Y; Xu JX; He HL; Chai YH; Zhao WL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):729-735. PubMed ID: 28641626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
    Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
    Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical value to quantitate hematogones in Chinese childhood acute lymphoblastic leukemia by flow cytometry analysis.
    Wang Y; Peng L; Dai Q; Ye L; Chen L; Chen Q; Lai C; Jiang Y; Zhang G
    Int J Lab Hematol; 2016 Jun; 38(3):246-55. PubMed ID: 26991766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.